BioCartilage / Scaffolds / AMIC

What It Is

→ BioCartilage and AMIC add a "helper layer" on top of microfracture. A scaffold (like a cartilage-protein sponge) gives healing cells a structure to grow on. Like providing scaffolding for construction workers instead of building in mid-air.

BioCartilage is dehydrated, micronized allogeneic cartilage containing extracellular matrix (type II collagen, proteoglycans, cartilaginous growth factors). It acts as a scaffold over microfractured defects [29].

→ Allogeneic = from a donor (not your own tissue); extracellular matrix = the "glue" between cells; proteoglycans = cushioning molecules in cartilage

Systematic Review Outcomes

AMIC 2024 Systematic Review and Meta-Analysis

A June 2024 systematic review of 15 studies (12 case series for meta-analysis) [31]:

→ AMIC = Autologous Matrix-Induced Chondrogenesis; combines microfracture with a collagen membrane

• VAS, AOFAS ankle-hindfoot, and Tegner scores at last follow-up showed statistically significant improvement (p<0.001)
  → Tegner score = activity level scale (0-10); higher = more active lifestyle
• VAS improved 4.45-4.6 points from baseline at 1-5 year follow-up

AMIC 10-Year Cohort Study (2025)

A 2025 study in Cartilage evaluated 10-year outcomes [73]:

• "Gold standard surgical treatment for OCLs of the talus still needs to be established"
• AMIC is a commonly applied 1-stage procedure with good short/mid-term results
  → 1-stage = done in a single surgery (vs 2-stage which requires harvesting cells, growing them, then implanting)
• 10-year cohort tracked FFI-D scores preop and at 1, 5, and 10 years
  → FFI-D = Foot Function Index (German version); measures pain and disability

Arthroscopic AMIC 5-Year Follow-Up (2026 CARTILAGE)

Efrima et al. evaluated arthroscopic AMIC at 24 and 60 months [74]:

• Significant clinical improvement maintained at 5 years; improvement peaks in first 2 years then plateaus
• Patients older than 33 had significantly worse outcomes
• Increased age and BMI associated with inferior results
• Arthroscopic approach shows promise for reduced morbidity

DGOU 2024: Scaffold Sizing Guidance

The German cartilage society guidelines now offer clear sizing thresholds [128]:

• BMS alone: only for lesions <1.0 cm² without bony defect
• Scaffold augmentation recommended for lesions >1.0 cm² and for cystic defects
• Warning: bone grafting alone has a 46% revision rate — scaffolds improve this significantly
• Arthroscopy has technical limits for radical debridement of extended cystic lesions

2024 EMCA/BioCartilage Systematic Review

A 2024 systematic review of 162 ankles across 5 studies found [29]:

• Subjective improvement and some MRI advantages over BMS alone
• However, no consensus on EMCA's precise role — longer comparative studies needed

Concerns

• High reoperation rate: 54.6% underwent subsequent surgery (mostly hardware removal) [33]
• Only 14% of revisions were graft-related complications [33]
• MaioRegen scaffold: 31% failure rate (5/16), 4 required prostheses [34]

For revision cases: This branch looks strongest when the surgeon treats it as a lower-morbidity bridge or bone-restoring/staging step, not as a definitive standalone answer for failed grafts.

Added August 3, 2026 — Arthrex is running a talus-specific BioCartilage study, and its complication profile is nerve-and-wound heavy

→ Found in the FDA's adverse-event database rather than in the literature. It means results for this exact use are coming, and it is the first look at what goes wrong.

A safety filing quotes its own source: “Information had been obtained from a clinical study, a pilot study to evaluate the efficacy of BioCartilage micronized cartilage matrix in microfracture treatment of osteochondral defects of the talus (US-01096)” [324]. Reported events include plantar-nerve involvement and possible tarsal tunnel syndrome, bilateral neurological changes, an infected suture, a 40° gastrocnemius contracture, and “a total of four (4) reoperations.” All were assessed by the manufacturer as unrelated to the device.

Read it for what it is. This is an aggregated manufacturer safety filing, not a results publication — there are no outcome scores, no denominator, and no way to know how many patients were enrolled. It does not say the technique failed. Two things follow that are worth carrying: a named talus-specific trial exists and its results should eventually publish, and the complications clustered around nerves and wound healing rather than around the graft, which is a question worth asking any surgeon proposing this approach. For a 15 × 10 mm cystic revision lesion, BioCartilage over microfracture remains a weaker option than autograft, allograft or cell therapy regardless.

Added September 7, 2026 — an independent review of the class reaches this page’s conclusion

An NYU Langone scoping review of cartilaginous non-structural allografts (BioCartilage, DeNovo NT, CartiMax), published September 7, concludes that BioCartilage “may improve radiographic defect fill” as a marrow-stimulation adjunct but has not consistently shown superior functional outcomes, and that the class as a whole lacks evidence of long-term functional superiority over marrow stimulation alone — making cost-effectiveness an open question [464]. The full write-up, including the DeNovo NT and CartiMax verdicts, is on topic 7.

Added September 23, 2026 — the injectable cousin of AMIC gets its first talus-specific meta-analysis — from the same Rizzoli group recruiting for the site’s best-matched trial

→ AMIC glues a collagen membrane over a microfractured defect; ACIC injects a collagen gel instead — same idea, no membrane to fix, and it can be done arthroscopically. A Bologna group pooled everything published on ACIC in the ankle: five studies, 97 patients. Scores improved a lot (function up ~27 points, pain down ~3.7 of 10) — but nearly all the studies had no comparison group, so nobody can yet say the gel adds anything over microfracture alone, and the authors say so plainly. The interesting footnote: the reviewers are the same Rizzoli team whose recruiting trial is the one registry entry whose entry criterion actually matches this ankle’s cyst.

This page’s ledger of marrow-stimulation adjuncts — AMIC’s fixed collagen membrane, BioCartilage’s allograft-matrix paste — gains its third family member. An IRCCS Rizzoli review in Medicina, online September 22, open access [488]: Autologous Collagen-Induced Chondrogenesis (ACIC) — microfracture plus an injectable atelocollagen scaffold gelled over the defect to stabilize the marrow clot and retain mesenchymal cells — systematically reviewed and meta-analyzed for osteochondral lesions of the talus: five studies, 97 patients, mean age 40.9. Pooled AOFAS improvement 26.54 points (95% CI 17.34–35.74); pooled VAS improvement −3.72 (95% CI −4.44 to −3.01); both p<0.001. The authors’ own verdict: consistent improvement in small, predominantly uncontrolled cohorts — the incremental benefit over microfracture alone remains uncertain, and adequately powered prospective head-to-head studies are needed.

Read it with its limits: five studies and 97 patients with essentially no comparative arms — a pooled before–after change is evidence that treated patients improved, not that the scaffold did the improving (the NYU scoping review above [464] reached the same structural verdict about this whole class); primary-lesion cohorts, not revision or post-allograft lesions; and AOFAS-led outcomes. For this ankle the entry is landscape, not plan — topic 3’s ledger already argues this lesion’s size, depth, and cyst make any marrow-stimulation-family technique a poor fit. Two things still earn it the carry: it is the first pooled talus-specific synthesis of the injectable-scaffold variant, completing this page’s membrane–paste–gel triptych; and its authorship is a thread the site is already holding — Antonio Mazzotti, the named contact of Rizzoli’s NCT07555899 (topic 33’s closest-match trial), sits on the author line. The group writing the evidence synthesis for scaffold adjuncts is the group enrolling the next-generation version — useful context for the email topic 33 keeps recommending.